Patents Assigned to Eisai R&D Management Co., Ltd.
-
Patent number: 11945807Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.Type: GrantFiled: May 3, 2022Date of Patent: April 2, 2024Assignee: EISAI R&D MANAGEMENT CO., LTD.Inventors: Ermira Pazolli, Silvia Buonamici, Thiwanka Samarakoon, Sudeep Prajapati, Nathan Fishkin, James Palacino, Michael Seiler, Ping Zhu, Andrew Cook, Peter Smith, Xiang Liu, Shelby Ellery, Dominic Reynolds, Lihua Yu, Zhenhua Wu, Shouyong Peng, Nicholas Calandra, Megan Sheehan, Yonghong Xiao
-
Patent number: 11925639Abstract: Provided is a pharmaceutical composition for treating a tumor, which is used in combination therapy of lenvatinib and (6S,9aS)—N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide.Type: GrantFiled: February 6, 2018Date of Patent: March 12, 2024Assignee: Eisai R&D Management Co., Ltd.Inventors: Yoichi Ozawa, Yusaku Hori, Kazuhiko Yamada, Hiroshi Kamiyama, Masahiro Matsuki
-
Patent number: 11926619Abstract: The present disclosure provides novel pladienolide compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancers, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are methods of treating cancers by administering at least one compound disclosed herein and at least one additional therapy.Type: GrantFiled: April 8, 2019Date of Patent: March 12, 2024Assignee: Eisai R & D Management Co., Ltd.Inventors: Gregg F. Keaney, John Wang, Baudouin Gerard, Kenzo Arai, Xiang Liu, Guo Zhu Zheng, Kazunobu Kira, Lisa A. Marcaurelle, Marta Nevalainen, Ming-Hong Hao, Morgan Welzel O'Shea, Parcharee Tivitmahaisoon, Sudeep Prajapati, Tuoping Luo, Nicholas C. Gearhart, Jason T. Lowe, Yoshihiko Kotake, Satoshi Nagao, Regina Mikie Kanada Sonobe, Masayuki Miyano, Norio Murai, Andrew Cook, Shelby Ellery, Atsushi Endo, James Palacino, Dominic Reynolds
-
Publication number: 20240060068Abstract: Gapmers or pharmaceutically acceptable salt of the gapmers and methods of making the gapmers are provided. The gapmers include a gap region that contains deoxyribonucleosides linked to each other by phosphorothioate bonds, a 5? wing region positioned at the 5? end of the gap region that contains morpholino monomers linked to each other by phosphorodiamidate bonds, and a 3? wing region positioned at the 3? end of the gap region that contains morpholino monomers linked to each other by phosphorodiamidate bonds. Antisense oligonucleotides are also provided. These antisense oligonucleotides are useful in the preparation of gapmers for inhibition of Tau mRNA transcription.Type: ApplicationFiled: December 10, 2021Publication date: February 22, 2024Applicant: Eisai R&D Management Co., Ltd.Inventors: Francis G. Fang, Dae-Shik Kim, Hyeong Wook Choi, Yoshinori Takahashi, Kenji Kikuta, Hikaru Kawashima, Wataru Itano, Toshiki Kurokawa, Tamaki Hoshikawa, Mingde SHAN, John Wang
-
Publication number: 20230406863Abstract: The present invention provides novel Compound (1) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, and medical uses thereof.Type: ApplicationFiled: June 21, 2023Publication date: December 21, 2023Applicants: President and Fellows of Harvard College, Eisai R&D Management Co., LTD.Inventors: Yoshito Kishi, Kazunobu Kira, Ken Ito
-
Patent number: 11833119Abstract: Provided herein is a combination therapy useful for the treatment hepatocellular carcinoma. The combination comprises an FGFR4 inhibitor and lenvatinib.Type: GrantFiled: January 9, 2019Date of Patent: December 5, 2023Assignee: EISAI R&D MANAGEMENT CO., LTD.Inventors: Anand Selvaraj, Peter Smith
-
Patent number: 11833146Abstract: There is provided a therapeutic agent for Alzheimer's disease and Lewy body dementia for combined use of (S)-7-(2-methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]quinoline-4(5H)-one represented by formula (1): or a pharmaceutically acceptable salt thereof, and donepezil represented by formula (II): or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 30, 2018Date of Patent: December 5, 2023Assignee: Eisai R&D Management Co., Ltd.Inventors: Mai Miyamoto, Sadaharu Kotani
-
Patent number: 11814398Abstract: The present invention provides novel compounds (e.g., compounds of Formulae (I), (II), (III), (IV)) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or pharmaceutically acceptable salts thereof, optionally in a pharmaceutically acceptable carrier, and a medical uses thereof.Type: GrantFiled: June 23, 2022Date of Patent: November 14, 2023Assignees: President and Fellows of Harvard College, Eisai R&D Management Co., LTD.Inventors: Yoshito Kishi, Kazunobu Kira, Ken Ito
-
Publication number: 20230301990Abstract: The present disclosure provides novel pladienolide compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are methods of treating cancers by administering at least one compound disclosed herein and at least one additional therapy.Type: ApplicationFiled: March 7, 2023Publication date: September 28, 2023Applicant: Eisai R&D Management Co., Ltd.Inventors: Andrew COOK, Dominic REYNOLDS, Cheng ZHONG, Ryan BRAWN, Shelby ELLERY, Thiwanka SAMARAKOON, Xiang LIU, Sudeep PRAJAPATI, Megan SHEEHAN, Jason T. LOWE, James PALACINO
-
Patent number: 11761045Abstract: Splice variants associated with neomorphic SF3B1 mutations are described herein. This application also relates to methods of detecting the described splice variants, and uses for diagnosing cancer, evaluating modulators of SF3B1, and methods of treating cancer associated with mutations in SF3B1.Type: GrantFiled: November 16, 2020Date of Patent: September 19, 2023Assignee: Eisai R&D Management Co., Ltd.Inventors: Lihua Yu, Kian Huat Lim, Jacob D. Feala, Silvia Buonamici, Yoshiharu Mizui, Peter G. Smith, Ping Zhu, Eunice Sun Park, Michael W. Seiler, Marco Peter Fekkes
-
Patent number: 11753669Abstract: Provided herein are conjugated immunoglobulins and methods for generating conjugated immunoglobulins using a microbial transglutaminase.Type: GrantFiled: January 27, 2021Date of Patent: September 12, 2023Assignee: Eisai R&D Management Co., Ltd.Inventors: Jared Spidel, Earl Albone
-
Publication number: 20230279018Abstract: The invention provides agents that inhibit L-Phe in cytoplasmic phenylalanine tRNA-synthetase (cFRS), methods for identifying them, compositions comprising such agents, and therapeutic methods of using such agents.Type: ApplicationFiled: March 22, 2023Publication date: September 7, 2023Applicants: The Broad Institute, Inc., President and Fellows of Harvard College, Eisai R&D Management Co., LTD.Inventors: Eamon COMER, Bruno MELILLO, Francis G. FANG, Branko MITASEV
-
Patent number: 11725015Abstract: The present invention provides novel Compound (1) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, and medical uses thereof.Type: GrantFiled: February 4, 2021Date of Patent: August 15, 2023Assignees: President and Fellows of Harvard College, Eisai R&D Management Co., LTD.Inventors: Yoshito Kishi, Kazunobu Kira, Ken Ito
-
Publication number: 20230250182Abstract: Provided herein are methods of treating cancer (e.g., RCC) or von-Hippel Lindau disease, which comprise administering to a human patient in need thereof: (a) a PD-1 antagonist; (b) a HIF-2? inhibitor; and (c) lenvatinib, or a pharmaceutically acceptable salt thereof. Also provided are kits containing such agents and uses of therapeutic combinations of such agents for the treatment of cancer.Type: ApplicationFiled: June 21, 2021Publication date: August 10, 2023Applicants: Merck Sharp & Dohme LLC, Eisai R&D Management Co., Ltd.Inventors: Rodolfo Fleury Perini, Elaine M. Pinheiro, Jacqueline Willemann-Rogerio
-
Patent number: 11707448Abstract: The present invention provides methods and compositions for treating cancer by administering an EP4 antagonist in combination with radiation therapy, antibody therapy and/or anti-metabolite chemotherapy.Type: GrantFiled: November 17, 2021Date of Patent: July 25, 2023Assignee: EISAI R&D MANAGEMENT CO., LTD.Inventors: Xingfeng Bao, Diana Albu, Mary Woodall-Jappe
-
Publication number: 20230212679Abstract: The purpose of the present invention is to provide a method for predicting the effectiveness of an angiogenesis inhibitor in a subject suffering from a tumor. Provided is a method comprising a step of testing for the presence or absence of an a mutation or loss of expression of B-Raf and PTEN in a sample of tumor tissue from the subject. By using the presence or absence of or a mutation or loss of expression of B-Raf and PTEN as an indicator, this method enables the antitumor effectiveness of the angiogenesis inhibitor to be predicted without administering the angiogenesis inhibitor to the subject.Type: ApplicationFiled: March 11, 2022Publication date: July 6, 2023Applicant: Eisai R&D Management Co., Ltd.Inventors: Taro Semba, Yusuke Narita, Yukinori Minoshima, Atsumi Yamaguchi, Yusuke Adachi, Kazuhiko Yamada, Junji Matsui, Tadashi Kadowaki, Kentaro Takahashi, Yasuhiro Funahashi
-
Publication number: 20230210838Abstract: Provided herein are methods of treating cancer (e.g., RCC) or von-Hippel Lindau disease, which comprise administering to a human patient in need thereof: (a) a HIF-2? inhibitor; and (b) lenvatinib, or a pharmaceutically acceptable salt thereof. Also provided are kits containing such agents and uses of therapeutic combinations of such agents for the treatment of cancer or von-Hippel Lindau disease.Type: ApplicationFiled: June 21, 2021Publication date: July 6, 2023Applicants: Merck Sharp & Dohme LLC, Eisai R&D Management Co., Ltd.Inventors: Rodolfo Fleury Perini, Elaine M. Pinheiro, Jacqueline Willemann-Rogerio
-
Patent number: 11691990Abstract: The present invention provides crystals of (1R,3R,15E,28R,29R,30R,31R,34R,36R,39S,41R)-29,41-Difluoro-34,39-bis(sulfanyl)-2,33,35,38,40,42-hexaoxa-4,6,9,11,13,18,20,22,25,27-decaaza-34?5,39?5-diphosphaoctacyclo[28.6.4.13,36.128,31.04,8.07,12.019,24.023,27]dotetraconta-5,7,9,11,15,19,21,23,25-nonaene-34,39-dione (Compound (I)) ammonium salts, Compound (I) sodium salts, or Compound (I), possessing a potential to be used as drug substance in pharmaceuticals.Type: GrantFiled: August 14, 2019Date of Patent: July 4, 2023Assignee: Eisai R&D Management Co., LTDInventors: Jun Niijima, Hirofumi Kuroda, So Yasui, Yoko Ito, Ikuo Kushida
-
Patent number: 11679107Abstract: The present disclosure provides pladienolide compounds, pharmaceutical compositions containing such compounds, and pladienolide compounds for use in methods of medical treatment. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful.Type: GrantFiled: April 11, 2019Date of Patent: June 20, 2023Assignee: EISAI R&D MANAGEMENT CO., LTD.Inventors: Andrew Cook, Dominic Reynolds, Cheng Zhong, Ryan Brawn, Shelby Ellery, Thiwanka Samarakoon, Xiang Liu, Sudeep Prajapati, Megan Sheehan, Jason T. Lowe, James Palacino
-
Publication number: 20230172867Abstract: The present invention relates to pharmaceutical compositions comprising an inhibitor of FGFR4, and methods of cancer therapy using the FGFR4 inhibitor. In particular, described herein are dosages of H3B-6527 with defined pharmacokinetic (PK) profiles that allow the inhibitor to be efficaciously and safely administered to a human subject in need thereof.Type: ApplicationFiled: May 14, 2021Publication date: June 8, 2023Applicant: Eisai R&D Management Co., Ltd.Inventors: Jianjun XIAO, Nathalie M. Rioux